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Background: The link between bacterial resistance and prognosis remains controversial. Predominant patho-
gen causing ventilator-associated pneumonia (VAP) is Pseudomonas aeruginosa (Pa), which has increasingly 
become multidrug resistant (MDR). The aim of this study was to evaluate the relationship between MDR VAP 
Pa episodes and 30-day mortality.
Methods: From a longitudinal prospective French multicenter database (2010-2016), Pa VAP onset and phys-
iological data were recorded. MDR was defined as non-susceptibility to at least 1 agent in 3 or more antimi-
crobial categories. To analyze if MDR episodes were associated with greater in-hospital 30-day mortality, we 
performed a multivariate survival analysis using the multivariate nonlinear frailty model.
Results: A total of 230 patients presented 286 Pa VAP. A maximum of 3 episodes per patient was observed; 
73 episodes were MDR and 213 were susceptible. In the multivariate model, factors independently associ-
ated with 30-day mortality included hospitalization in the 6 months preceding the first episode (hazard ratio 
[HR], 2.31; 95% confidence interval [CI], 1.50-3.60; P = .0002), chronic renal failure (HR, 2.34; 95% CI, 1.15-
4.77; P = .0196), and Pa VAP recurrence (HR, 2.29; 95% CI, 1.79-4.87; P = .032). Finally, MDR Pa VAP was not 
associated with death (HR, 0.87; 95% CI; 0.52-1.45; P = .59).
Conclusions: This study did not identify a relationship between the resistance profile of Pseudomonas aerugi-
nosa and mortality.Multidrug resistance
Recurrence
Ventilator-associated pneumonia
Intensive care medicine
Empirical antiobiotic
Nosocomial pneumoniastance Publique - Hôpitaux de
espiratoires et des Infections
enis).BACKGROUND
Nosocomial pneumonia is the most frequently reported infection
in intensive care units (ICUs), with mechanically ventilated patientsbeing at the highest risk. The incidence of ventilator-associated pneu-
monia (VAP) ranges from 8% to 28% of mechanically ventilated
patients.1 The incidence density of VAP is between 1.9 and 3.8 per
1000 ventilator-days in the United States and exceeds 18 per 1000
ventilator-days in Europe.2 These discrepancies are at least partly
explained by the definition used for diagnosis.3 Pseudomonas aerugi-
nosa (Pa) is the most common bacteria causing VAP (along with
Staphylococcus aureus), with a prevalence of 4.1% in a prospective
international observational study performed in 11 countries.4
The treatment of VAP related to Pa is challenging because of the
emergence and increased incidence of antibiotic resistance. Multi-
drug resistance varies from country to country and can be as high as
40%;5 however, there is no definite established relationship between
multidrug resistance and outcomes. Attributable mortality related to
multidrug-resistant (MDR) Pa has not been extensively studied. A
recent study6 reported that, compared to susceptible Pa VAP, the
MDR Pa VAP adjusted risk ratio of ICU death was 1.34 (95% CI, 0.97-
1.87), suggesting that the impact on ICU mortality is indirect via an
increased length of stay, which is consistent with the literature.7 The
aim of the present study was, therefore, to evaluate the relationship
between MDR Pa VAP episodes and mortality in a series of mechani-
cally ventilated patients.METHODS
Study population and data collection
We conducted a retrospective study in 3 ICUs from 2 French hos-
pitals between January 2010 and December 2016. The analysis was
based on records from a longitudinal prospectively collected data-
base. The study was approved by the Commission Nationale de l’In-
formatique et des Libertes (CNIL #CIL/AP-HM 2017/48).
Eligible patients were ≥18 years old, were consecutively admitted
to the ICU, had a diagnosis of VAP according to Infectious Diseases
Society of America criteria,8 and had a microbiologic confirmation of
monomicrobial Pa culture. The onset of each VAP episode was consid-
ered at the time the microbiologic sample was obtained. The follow-
ing data were collected: age, sex, comorbidities, origin and reason for
ICU admission, organ failure scores (Sepsis-Related Organ Failure
Assessment and Simplified Acute Physiology Score II), duration of
mechanical ventilation, length of ICU stay, length of hospital stay, and
30-day mortality.
Information concerning each VAP episode or recurrence was also
collected, including the Sepsis-Related Organ Failure Assessment,
antimicrobial treatment received, initiation of empiric antibiotic ther-
apy (and its adequacy), delay between sampling and adequate antibi-
otic therapy, patterns of germ resistance, associated organ failures
(septic shock, acute respiratory distress syndrome, acute kidney
injury), and the absence/presence of bacteremia within the 48 hours
before and/or after VAP episode diagnosis.Definitions
The diagnosis of VAP was retained according to the Infectious Dis-
eases Society of America definition:8 VAP refers to pneumonia that
occurs more than 48 to 72 hours after endotracheal intubation. Colo-
nization is defined by a positive respiratory microbiological sampling
of Pa prior to VAP with no clinical, radiological, or biological signs of
respiratory infection. The microbiological confirmation was obtained
by bronchoalveolar lavage, quantitative culture with a threshold at
104 CFU/mL, or tracheal aspiration quantitative culture at a threshold
of 105 CFU/mL. Multidrug resistance was defined as non-susceptibil-
ity to at least 1 agent in 3 or more antimicrobial categories.9
Empirical antibiotic therapy was considered when an antimicro-
bial regimen was administered within 24 hours of the sample for VAP
diagnosis and before susceptibility was known. Antimicrobial therapy
was considered adequate when the Pa isolate was susceptible to at
least 1 of the antimicrobial agents prescribed. Recurrence was defined
as the persistence or recurrence of the VAP criteria defined above,
documented as Pa at least 2 days after the end of antibiotic therapy
initiated for the previous episode.10 The main outcome was all-cause
in-hospital mortality at day 30 (30-day mortality).Statistical analysis
We first described the characteristics of the patients and the epi-
sodes. Quantitative data are presented as means § standard devia-
tions (SDs) or medians (interquartile ranges [IQRs]). Qualitative data
are presented as counts and percentages (%). We then compared epi-
sodes of MDR Pa VAP to susceptible Pa episodes. To take into account
correlations due to multiple episodes per subject, we performed uni-
variate generalized mixed models with random interception. We
used the PROC GLIMMIX procedure available in SAS 9.4 (SAS Insti-
tute; Cary, NC).
To analyze if MDR episodes were associated with higher in-hos-
pital 30-day mortality, we performed a multivariate survival analy-
sis using the multivariate nonlinear frailty model (with a gamma
distribution of the frailty) of these repeated episodes of VAP, as
well as a common origin (the start of the first episode) for each
individual’s event. The frailty model allowed us to take into account
unobserved heterogeneity due to correlation of data (because of
repeated episodes per subject). The subject was defined as a ran-
dom effect. Thirty-day mortality was defined as the event. Patients
still alive at day 30 following the start of VAP were censored,
in addition to patients with a recurrence within these 30 days
(with time to censoring = time to recurrence). After introducing
all variables with a P value < .20 in univariate analyses, we per-
formed a backward selection using a threshold of .05 for statistical
significance. The model was run with the PROC PHREG procedure
available in SAS 9.4.
RESULTS
Characteristics of the patients
A total of 230 patients with Pa VAP were included during this 7-
year period. As shown in Table 1, acute respiratory failure was the
leading cause of admission (53.5%). Sixty percent of the patients were
admitted from the ward. The median duration of ventilation was
25 days (IQR, 15-45). The median length of ICU stay was 34 days (IQR,
20-53), and the crude ICU mortality was 53%. The mortality on day 30
was 22%.
Characteristics of the episodes of Pseudomonas aeruginosa VAP
A maximum of 3 episodes per patient was observed. Figure 1
shows the distribution of the 286 Pa VAP episodes. A total of 73 epi-
sodes were MDR: 51 (22.2%) at the first episode of VAP, 19 (40.4%) at
the second episode, and 3 (33.3%) at the third episode; 213 episodes
were susceptible: 179 (77.8%) at the first episode, 28 (59.9%) at the
second episode, and 6 (66.7%) at the third episode.
Comparison between MDR Pa episodes of VAP and susceptible Pa
episodes of VAP
Hospitalization in the 6 months preceding the first episode of VAP
due to Pa was more common in the MDR group (P = .002) (Table 2).
More patients had received antibiotics in the previous 30 days before
VAP due to Pa in the MDR group (P = .02). There were also more
patients admitted from the ward (P = .003), more patients presenting
with cystic fibrosis (P = .0001), more lung transplant recipients (P <
.0001), more patients presenting with immunosuppression
(P = .0003), and more patients presenting with Pa colonization before
VAP (P = .006) in the MDR group. More patients from the MDR Pa VAP
group received inadequate empiric antibiotic therapy (18.4% vs 4.7%;
P = .002). Finally, Pa VAP recurrence (second or third episode) was
more common in the MDR group (P = .018).
Table 1
Characteristics of the population
Variable Patients (N = 230)
Male gender, n (%) 164 (71.3)
Age (y), median (IQR) 60 (47−69)
SAPS II, median (IQR) 45 (36-59)
SOFA, median (IQR) 7 (5-9)
Admission category, n (%)
Medicine 134 (58.3)
Emergency surgery 46 (20)
Scheduled surgery 21 (9.1)
Trauma 29 (12.6)
Origin of admission, n (%)
Direct admission 92 (40)
ICU admission cause, n (%)
Acute respiratory failure 123 (53.5)
Acute neurology failure 41 (17.8)
Septic shock 28 (12.2)
Acute heart failure 16 (7)
Other 22 (9.6)
Chronic illnesses, n (%)
Cardiovascular 66 (28.7)
Renal 14 (6.1)
Liver 7 (3)
Diabetes 48 (20.9)
COPD 39 (17)
Cystic fibrosis 18 (7.8)
Immunosuppression 48 (20.9)
Malignancies 51 (22.2)
Hospitalization in the last 6 mo, n (%) 94 (40.9)
Antibiotic in the last 30 d, n (%) 67 (29.1)
Pseudomonas colonization before VAP, n (%) 79 (34.3)
COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IQR, interquar-
tile range; SAPS II, Simplified Acute Physiology Score II; SOFA, Sepsis-Related Organ
Failure Assessment; VAP, ventilator-associated pneumonia.Factors associated with day-30 mortality
Among all the 286 VAP episodes, 99 led to death before recurrence
within 30 days. In the univariate analysis, factors associated with 30-
day mortality were age, hospitalization in the 6 months preceding
the first episode, use of antibiotics in the previous 30 days, chronicFig 1. Flow chart of the study. First, Second, and Third refer to the first, second, and third
MDR, multiple drug-resistant Pseudomonas aeruginosa; S, non-MDR P aeruginosa.renal failure, and malignancies (Table 3). The absence of empiric anti-
biotic therapy was identified as a significant protective factor (HR,
0.41; 95% CI; 0.21-0.82; P = .012). The factors associated with the
severity of the episode were associated with an increased risk of
death (septic shock, acute respiratory distress syndrome, acute kid-
ney injury). Pa VAP recurrence was also associated with death (HR,
2.26; 95% CI; 1.43-5.71; P = .003). In the multivariate model (with
resistance as a forced variable), factors independently associated
with 30-day mortality were age (HR, 1.02; 95% CI, 1.01-1.04;
P = .0064), hospitalization in the 6 months preceding the first episode
(HR, 2.31; 95% CI, 1.50-3.60; P = .0002), chronic renal failure (HR,
2.34; 95% CI, 1.15-4.77; P = .0196), and Pa VAP recurrence (HR, 2.29;
95% CI, 1.79-4.87; P = .032). In contrast, this analysis indicated that an
episode of resistant Pa VAP was not considered a risk factor for death
(HR, 0.87; 95% CI, 0.52-1.45; P = .60).
DISCUSSION
This study showed that the resistance profile of Pseudomonas aer-
uginosa responsible for VAP was not associated with death. In con-
trast, the underlying condition of the patients at the time of VAP
diagnosis was associated with death. The fact that recurrence is a fac-
tor associated with mortality shows that the more a patient worsens
and remains on mechanical ventilation, the greater the risk of recur-
rence and death. However, the resistance of Pa also increases with
recurrence.
In our study, we considered also as a recurrence the persistence of
VAP occurring 2 days after the end of treatment. This may have
included patients with unapparent resolution because of getting
inappropriate antibiotic therapy from MDR Pa VAP in the previous
episode; however, we did not find any link between adequacy or
inadequacy of empiric antibiotic therapy and recurrence. Moreover,
the analysis was adjusted on adequate/inappropriate antibiotic ther-
apy, thus limiting the impact of potentially imbalanced groups on
this factor.
In a univariate study, not having empiric antibiotherapy was a
protective factor, compared to having an inadequate one (HR, 0.41;
95% CI, 0.21-0.82; P = .0120). This can be explained by the wait-and-
see strategy in less severe patients, which is based on waiting forPseudomonas aeruginosa episodes, respectively. VAP, ventilator-associated pneumonia;
Table 2
Factors associated with MDR VAP episodes
Variable
MDR
(n = 73)
Susceptible
(n = 213) P value
Male gender, n (%) 54 (74.0) 154 (72.3) .83
Age, years median (IQR) 58 (42-65) 60 (48-70) .36
SAPS II, median (IQR) 40 (31-50) 45 (36-58) .35
SOFA, median (IQR) 6 (4-9) 6 (4-9) .83
Admission category, n (%) .06
Medicine 45 (61.6) 118 (55.4)
Emergency surgery 20 (27.4) 38 (17.8)
Scheduled surgery 5 (6.8) 22 (10.3)
Trauma 3 (4.1) 35 (16.4)
Hospitalization in the last 6 mo, n (%) 41 (56.2) 71 (33.3) .003
Antibiotic in the last 30 d, n (%) 30 (41.1) 52 (24.4) .02
Origin of admission, n (%)
Direct admission 18 (24.7) 98 (46.0) .003
Chronic illnesses, n (%)
Cardiovascular 15 (20.5) 68 (31.9) .09
Kidney 3 (4.1) 11 (5.2) .76
Liver 2 (2.7) 6 (2.8) .88
Diabetes 19 (26.0) 43 (20.2) .35
COPD 16 (21.9) 32 (15.0) .26
Cystic fibrosis 16 (21.9) 7 (3.3) <.0001
Lung transplantation 23 (31.5) 20 (9.4) .0001
Immunosuppression 29 (39.7) 33 (15.5) .0003
Malignancies 13 (17.8) 50 (23.5) .36
Pseudomonas colonization before VAP, n (%) 36 (49.3) 63 (29.6) .006
Pseudomonas bacteremia within 48 h of VAP, n (%) 7 (9.6) 12 (5.7) .26
Septic shock within 48 h of VAP, n (%) 42 (57.5) 116 (54.5) .70
ARDS within 48 h of VAP, n (%) 50 (68.5) 148 (69.5) .95
AKI within 48 h of VAP, n (%) 20 (27.4) 38 (17.8) .14
Empiric antibiotic therapy, n (%) .002
Absence of empiric antibiotic therapy 30 (42.3) 69 (32.5)
Inadequate empiric antibiotic therapy 13 (18.3) 10 (4.7)
Adequate empiric antibiotic therapy 28 (39.4) 133 (62.7)
Adequate antibiotic therapy within 24 h, n (%) 35 (47.9) 125 (58.7) .13
Delay between the onset of mechanical ventilation
and VA (d), median (IQR)
18 (9-34) 15 (7-27) .26
One or more recurrences, n (%) 22 (30.14) 34 (16.0) .018
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; IQR, interquartile range;MDR, multiple drug-resistant Pseudomo-
nas aeruginosa; SAPS II, Simplified Acute Physiology Score II; SOFA, Sepsis-Related Organ Failure Assessment; VAP, ventilator-associated pneumonia.
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identification of the germ and antibiogram; however, this relation-
ship was no longer found in the multivariate model.
The retrospective nature of our study is a limitation, although
missing data are scarce due to prospective data capture. Interesting
data such as the delay between the onset of VAP and introduction of
the antibiotic treatment were not available. In the other limits of our
study, we can emphasize that we have never been in a situation of
therapeutic impasse.
In the literature, the risk of acquiring VAP is highest during the
first 5 days of mechanical ventilation (3%), with the mean duration
between intubation and development of VAP being 3.3 days.11,12 This
risk declines to 2% per day between days 5 and 10 of ventilation, and
1% per day for the remaining days.4 Chronic obstructive pulmonary
disease, duration of mechanical ventilation longer than 8 days, and
prior use of antibiotics are already known risk factors for Pa.13
In the ICU, VAP is associated with a death rate of approximately
20%;7 however, the mortality attributable (percentage of deaths that
would not have occurred in the absence of the infection) to this infec-
tion remains debated, with an estimated value between 5% and
13%.14 One of the explanations for this huge variability is related to
the difficulty of a statistical model to determine the VAP-associated
mortality across many risk factors for death. Taking into account both
the temporal dependence of the risk factor (VAP) and the presence of
competing risks (death and discharge) by using a multistate model,
Nguile-Makao et al15 reported that VAP-associated mortality was
only 8.1% for a 120-day period of observation. Being a surgical patientor having an intermediate Simplified Acute Physiology Score II score
at ICU admission was associated with a higher VAP-associated mor-
tality. These results were also reported after performing a competing
risk analysis.14 VAP-associated mortality linked to Pa is difficult to
establish clearly. A 20% increase in the risk of dying in the ICU for
patients presenting VAP due to Pa has recently been reported.6 The
authors concluded that the risk of death seems related to a decreased
discharge hazard. Thus, the effect on mortality could be indirect due
to a prolonged ICU stay. Our results are consistent with these conclu-
sions; however, the advantage of our study is that it analyzes in-hos-
pital mortality at day 30 and not only ICU mortality which allows us
to eliminate a competitive risk bias.6 Moreover, considering all epi-
sodes, we made the link between mortality and recurrence, rather
than resistance. Understanding the impact of Pa resistance on the
outcome is challenging. The first reason is that there is no interna-
tional consensus on the definition of multidrug resistance, which
makes direct comparison of the literature difficult; however, interna-
tional experts recently proposed a standardized definition of resis-
tance.9 These resistant strains are potentially associated with
inappropriate empiric antibiotic treatment, which is a main determi-
nant of mortality in patients with pneumonia in the ICU.16 Multidrug
resistance, therefore, decreases treatment options and increases the
risk of delaying treatment.17 The relationship between initial antibi-
otic inadequacy and early mortality has already been reported, but
the role of multidrug resistance remains controversial;18 therefore, it
is crucial to investigate if VAP related to resistant strains of Pa is
Table 3
Factors associated with day 30 in hospital mortality: univariate and multivariate frailty model
Variable
Survivor
(n = 187)
30-day deaths
(n = 99)
Univariable
analysis P value
Multivariable
analysis P value
Male gender, n (%) 141 (75.4) 67 (67.7) 0.73 (0.48-1.12) .15 0.56 (0.35-0.89) .013
Age (y), median (IQR) 57 (42-67) 63 (52-70) 1.01 (1.01-1.03) .022 1.02 (1.01-1.04) .0064
Hospitalization in the last 6 mo, n (%) 57 (30.5) 55 (55.6) 2.26 (1.51-3.40) <.0001 2.31 (1.50-3.60) .0002
Antibiotic in the last 30 d, n (%) 41 (21.9) 41 (41.4) 2.03 (1.35-3.04) .0006
Admission category, n (%) .06
Medicine 98 (52.4) 65 (65.7) 3.30 (1.32-8.24)
Emergency surgery 40 (21.4) 18 (18.2) 2.43 (0.90-6.55)
Scheduled surgery 16 (8.6) 11 (11.1) 3.57 (1.21-10.53)
Trauma 33 (17.6) 5 (5.0) 1
Origin of admission, n (%)
Direct admission 82 (43.8) 34 (34.3) 1.35 (0.89-2.05) .16
Chronic illnesses, n (%)
Cardiovascular 50 (26.7) 33 (33.3) 1.29 (0.84-1.97) .24
Kidney 5 (2.7) 9 (9.1) 2.20 (1.10-4.40) .0253 2.34 (1.15-4.77) .0196
Liver 3 (1.6) 5 (5.0) 2.37 (0.96-5.88) .06
Diabetes 41 (21.9) 21 (21.2) 0.99 (0.61-1.61) .97
COPD 28 (15.0) 20 (20.2) 1.34 (0.85-2.29) .18
Cystic fibrosis 14 (7.5) 9 (9.1) 1.13 (0.57-2.26) .72
Lung transplantation 29 (15.5) 14 (14.1) 0.85 (0.47-1.53) .58
Immunosuppression 36 (19.2) 26 (26.3) 1.28 (0.81-2.04) .29
Malignancies 30 (16.0) 33 (33.3) 1.93 (1.26-2.96) .0024
Pseudomonas colonization before VAP, n (%) 68 (36.4) 31 (31.3) 1.30 (0.84-2.01) .23
SAPS II, median (IQR) 44 (35 − 53) 43 (36 − 62) 1.01 (0.99-1.02) .14
SOFA, median (IQR) 5 (3-8) 8 (6-11) 1.23 (1.16-1.31) <.0001 1.17 (1.10-1.25) <.0001
Delay between the start of mechanical
ventilation and VAP (d), median (IQR)
16 (8-29) 12 (6-28) 0.99 (0.98-1.00) .17
Empiric antibiotic therapy, n (%) .0410 .0386
Absence of empiric antibiotic therapy 72 (38.5) 27 (27.3) 0.41 (0.21-0.82) .0120 0.61 (0.30-1.25) .20
Inadequate empiric antibiotic therapy 10 (5.3) 13 (13.1) 1 1
Adequate empiric antibiotic therapy 104 (55.6) 57 (57.6) 0.58 (0.31-1.08) .09 0.43 (0.22-0.85) .014
Effective antibiotic therapy within 24 h, n (%) 101 (54.0) 59 (59.6) 1.22 (0.82 − 1.82) .34
Pseudomonas bacteremia within 48 h of VAP, n (%) 10 (5.3) 9 (9.1) 1.36 (0.65-2.81) .41
Septic shock within 48 h of VAP, n (%) 84 (44.9) 74 (74.7) 3.03 (1.92-4.78) <.0001
ARDS within 48 h of VAP, n (%) 111 (59.4) 87 (87.9) 4.13 (2.25-7.57) <.0001 3.46 (1.78-6.79) .0003
AKI within 48 h of VAP, n (%) 26 (13.9) 32 (32.3) 2.32 (1.52-3.57) .0001
VAP with resistant Pseudomonas, n (%) 45 (24.1) 28 (28.3) 1.18 (0.71-1.75) .63 0.87 (0.52-1.45) .60
One or more recurrences, n (%) 32 (17.1) 24 (24.2) 2,86 (1.43-5.71) .003 2.29 (1.79-4.87) .032
AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SAPS II, Simplified Acute Physiology
Score II; SOFA, Sepsis-Related Organ Failure Assessment; VAP, ventilator-associated pneumonia.associated with an increased risk of death compared to more suscep-
tible strains. The absence of a difference would indicate that VAP is
not a major contributing factor to ICU death and/or that Pa pathoge-
nicity varies according to its phenotype. Another explanation would
be that attributable VAP mortality is more related to the severity of
the infectious episode than the antibiotic resistance itself.10 Aloush et
al19 reported a non-significant increase in crude in-hospital mortality
with MDR Pa colonization or infection compared with their matched
control patients. A significant association with mortality was reported
for MDR Pa colonization or infection when using a multivariate model
(odds ratio, 4.4; P = .04).16 However, not all patients were hospitalized
in the ICU, and infections and colonizations were not distinguished in
the many sites that were considered (wound, bloodstream, VAP, uri-
nary tract). The association between multidrug resistance and
increased ICU length of stay has already been reported.1
The absence of a link between multiresistance and mortality
allows us to evoke bacterial fitness. Fitness is defined as the ability of
bacteria to adjust its metabolism to suit environmental conditions in
order to survive and grow. The selection pressure exerted by antibiot-
ics has a fitness cost.20 This study allows a clinical approach. In con-
clusion, our study does not find any link between the resistance
profile of Pseudomonas aeruginosa and mortality. Further studies are
needed to evaluate if this is reported in large prospective studies.References
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